David L. Morris

ORCID: 0000-0001-9377-8521 · 6 papers in corpus
2025
Techniques in coloproctology ·doi:10.1007/s10151-024-03095-y

BackgroundThe goal of cytoreductive surgery for peritoneal malignancy is to remove all macroscopic disease, which occasionally requires the excision of the umbilicus. While the absence of the umbilicus can be aesthetically undesirable for p…

2023
Cancers ·doi:10.3390/cancers15194704

Malignant peritoneal mesothelioma (MPM) is an extremely rare malignancy usually confined to the abdominal cavity. With an aggressive natural history, morbidity and mortality are consequences of progressive locoregional effects within the pe…

2014
Orphanet journal of rare diseases ·doi:10.1186/1750-1172-9-71

Pseudomyxoma peritonei (PMP, ORPHA26790) is a clinical syndrome characterized by progressive dissemination of mucinous tumors and mucinous ascites in the abdomen and pelvis. PMP is a rare disease with an estimated incidence of 1-2 out of a …

2012
Cancer metastasis reviews ·doi:10.1007/s10555-011-9337-5

Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis which drives endothelial cell survival, proliferation, and migration while increasing vascular permeability. Playing an important role in the physiology of normal …

2011
Journal of medical case reports ·doi:10.1186/1752-1947-5-36

IntroductionMalignant peritoneal mesothelioma is a rare cancer with poor patient survival. Female gender has been identified as a positive prognostic factor. Recently, it has been suggested that the expression of estrogen receptor β in mali…

article 2006
·doi:10.1158/1078-0432.ccr-05-1181

Abstract Purpose: Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation. We have recently shown that …